NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-09-09 17:25இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Natural Capsules Shareholders Approve Preferential Issue of Shares and Warrants at EGM
Natural Capsules Limited announced that shareholders have approved two special resolutions at the Extraordinary General Meeting held on September 09, 2026. The resolutions cover the issuance of equity shares and convertible warrants on a preferential basis, both passing with over 99.99% approval. A total of 3,090,923 votes (99.994%) supported the share issuance, while 3,090,901 votes (99.993%) approved the convertible warrants. Specific issue sizing, pricing, and gross proceeds were not detailed in the Scrutinizer's report.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders officially passed special resolutions authorizing the board to issue equity shares and convertible warrants on a preferential basis.
ஏன் இது முக்கியம்The company has reported negative TTM PAT of Rs -25 Cr and requires capital to fund operations, API commercialization, and HPMC line expansions.
📅 குறுகிய காலம்Clearance removes regulatory shareholder approval hurdles, paving the way for allotment and capital inflow.
📈 நீண்ட காலம்Proceeds could provide essential liquidity to support API facility ramp-up toward cash breakeven and expand HPMC capsule lines.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution from new shares and warrant conversions
Issue price and capital quantum not disclosed in this specific filing
👀 கவனிக்க வேண்டியவை
Track subsequent exchange filings for the allotment details, issue price, total capital raised, and dilution impact on the existing equity base.
Natural Capsules revises preferential issue terms; to raise ₹10.01 Cr from promoter at ₹178/share
Natural Capsules Limited has issued a corrigendum to its EGM notice for the meeting scheduled on September 9, 2026, revising the issue price and quantity for its proposed preferential issue following exchange queries and a fresh valuation report. The company plans to issue 1,12,500 equity shares (aggregating ₹2.00 Cr) and 4,50,000 convertible warrants (aggregating ₹8.01 Cr) at ₹178 per share/warrant to promoter Sunil Laxminarayan Mundra. Total capital infusion stands at ₹10.01 Cr (approx. 4.5% of current market cap), increasing total promoter holding from 50.92% to 53.44% on a fully diluted basis.
உச்சம் நம்பிக்கை
என்ன மாறியதுNatural Capsules modified the preferential allotment terms, fixing the price at ₹178 per share/warrant for 1.125 lakh equity shares and 4.50 lakh convertible warrants following BSE/NSE queries.
ஏன் இது முக்கியம்Provides ₹10.01 Cr of direct equity liquidity from the promoter to support operations and API ramp-up amid recent quarterly losses.
வெளியீட்டு விலை: ₹178 per shareTotal fundraise: ₹10.01 கோடிFundraise vs Market Cap: ~4.5%Promoter post-issue stake: 53.44%EGM Date: செப்டம்பர் 09, 2026
📅 குறுகிய காலம்Shareholder approval at the September 9, 2026 EGM and subsequent in-principle exchange approvals will be key milestones over the coming weeks.
📈 நீண்ட காலம்Promoter capital infusion signals internal commitment, but sustained turnaround depends on the API segment reaching break-even capacity utilization.
⚠ அபாய எச்சரிக்கைகள்
Preferential price of ₹178 is below the current market price of ₹216.20.
Dilution of public shareholding from 49.08% to 46.56%.
👀 கவனிக்க வேண்டியவை
Track voting results from the EGM on September 9, 2026, stock exchange listing approvals, and subsequent deployment of funds into scaling the API division.
Natural Capsules Calls EGM for ₹2 Cr Preferential Equity Issue to Promoter at ₹160
Natural Capsules Limited has issued a notice for an Extraordinary General Meeting (EGM) on September 09, 2026, to approve preferential allotments. The company plans to issue 1,25,000 equity shares at ₹160.00 per share to promoter Sunil Laxminarayan Mundra, raising ₹2.00 crore, alongside convertible warrants. The issue price of ₹160.00 is at a premium to the current market price of ₹148.30. The fundraise quantum is modest, representing approximately 1.3% of the company's current market cap of ₹153 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுNatural Capsules has formally convened an EGM to approve a preferential equity and warrant issuance to its promoter.
ஏன் இது முக்கியம்Promoter infusion at a premium (₹160 vs ₹148.3 CMP) signals promoter backing amid recent quarterly losses, though the capital addition (₹2 Cr) is small relative to TTM revenue of ₹177 Cr.
Equity shares to be allotted: 1,25,000Issue price per share: ₹160.00Total equity issue size: ₹2.00 கோடிIssue size vs Market Cap: ~1.3%EGM date: செப்டம்பர் 09, 2026Relevant date: ஆகஸ்ட் 10, 2026
📅 குறுகிய காலம்Shareholders will vote at the September 09 EGM; market sentiment is typically supported by promoter buying at a premium to market price.
📈 நீண்ட காலம்Limited direct balance sheet impact due to the small size (₹2 Cr), though it supports liquidity as the company works to scale its API and capsule lines toward profitability.
⚠ அபாய எச்சரிக்கைகள்
Minor equity dilution
Company is currently loss-making at TTM net profit of ₹-25 Cr
👀 கவனிக்க வேண்டியவை
Track the shareholder voting outcome at the EGM on September 09, 2026, and watch for subsequent allotment disclosures within 15 days of approval.
Natural Capsules Q1 FY27: Revenue up 8% YoY to ₹48.71 Cr; API Segment Scaling Progresses
Natural Capsules Limited (NCL) reported a Q1 FY27 revenue of ₹48.71 Cr, an 8% YoY increase, though it remains loss-making with a PAT of ₹-5.74 Cr. The company is strategically converting HPMC capsule lines to gelatin due to erratic US demand and duty uncertainties to protect margins. The API segment is showing operational progress with the commencement of contract manufacturing for Fermbox Bio and gram-scale synthesis of Prednisolone. Management is targeting WHO GMP certification by Q2 FY27 to facilitate scaling of the API business, which currently requires significantly higher utilization to reach cash break-even.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is pivoting its HPMC capacity to gelatin lines to optimize utilization and has initiated its first contract manufacturing batches in the API segment.
ஏன் இது முக்கியம்The API division is currently the primary driver of losses; achieving commercial scale and regulatory approvals is critical for the company's turnaround and long-term profitability.
📅 குறுகிய காலம்The market will likely focus on the recovery of sales deferred by the ERP implementation and the impact of HPMC-to-gelatin line conversions on margins in the next quarter.
📈 நீண்ட காலம்Structural growth depends on the successful transition to high-value steroidal APIs and regulated market exports, which are currently hampered by technical scaling challenges and trade regulations.
⚠ அபாய எச்சரிக்கைகள்
Continued quarterly losses
High utilization required for API break-even
Erratic US demand for HPMC capsules
Geopolitical headwinds affecting African exports
👀 கவனிக்க வேண்டியவை
Monitor the progress of the WHO GMP audit expected in Q2 FY27 and the successful commercial production of the first backward-integrated Prednisolone batch by September-end.
Natural Biogenex Appoints K. H. Honneshaiah as COO to Lead API Operations
Natural Capsules Limited (NCL) has appointed Mr. K. H. Honneshaiah as the Chief Operating Officer (COO) of its material unlisted subsidiary, Natural Biogenex Private Limited. This appointment is significant as the subsidiary manages the steroidal API facility, which currently requires a capacity utilization of 25-30% (approx. ₹100 cr revenue) to reach cash break-even. The new COO brings 36 years of experience in regulated API manufacturing and greenfield scaling, addressing a critical leadership need for a segment that has contributed to NCL's TTM net loss of ₹19 cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுNatural Capsules has hired a veteran operations leader to head its material API subsidiary, Natural Biogenex.
ஏன் இது முக்கியம்The API segment is the company's primary growth engine but also its largest current financial drag; veteran leadership is essential to transition from lab-scale to profitable commercial production.
COO Experience: 36 yearsAPI Break-even Revenue Target: ₹100 கோடிTTM Net Profit: ₹-19 crசந்தை மதிப்பு: ₹161 கோடி
📅 குறுகிய காலம்The market may view this as a proactive step to address operational bottlenecks in the API division, potentially stabilizing sentiment after a 25% share price decline over 12 months.
📈 நீண்ட காலம்If the new COO successfully scales the API facility to the required 25-30% utilization, it could structurally pivot the company from losses to profitability.
⚠ அபாய எச்சரிக்கைகள்
Execution risk in scaling complex steroidal API production
High current cash burn in the subsidiary
👀 கவனிக்க வேண்டியவை
Investors should monitor the next two quarters for improvements in API capacity utilization and a reduction in quarterly losses, which have recently averaged ₹5-7 cr per quarter.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
₹10 Cr Promoter Fundraise Approved Amidst ₹5.74 Cr Q1 Net Loss
Natural Capsules Limited (NCL) reported a consolidated net loss of ₹5.74 Cr for Q1 FY27, compared to a loss of ₹5.58 Cr in the same quarter last year. While revenue grew 7.7% YoY to ₹48.71 Cr, the API segment remains a significant drag, posting a loss of ₹8.04 Cr on revenue of just ₹5.69 Cr. To bolster the balance sheet, the board approved a ₹10 Cr fundraise through a preferential issue of equity and warrants to promoters at ₹160 per share, which is a slight premium to the current market price. This infusion represents approximately 6.2% of the company's current market capitalization.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has initiated a ₹10 Cr capital infusion from promoters and reported Q1 FY27 results showing continued operational stress in the API division.
ஏன் இது முக்கியம்The promoter funding provides a necessary liquidity cushion as the company struggles with losses and high interest costs while trying to scale its complex steroidal API and HPMC capsule lines.
Fundraise vs Market Cap: ~6.2%Q1 Net Loss: ₹5.74 கோடிAPI Segment Revenue: ₹5.69 கோடிAPI Segment Loss: ₹8.04 கோடிIssue Price per Share: ₹160
📅 குறுகிய காலம்The stock may see support from the promoter's decision to infuse capital at a premium (₹160 vs CMP ₹159.1), but the weak quarterly earnings will likely cap gains.
📈 நீண்ட காலம்The long-term trajectory depends entirely on the API segment reaching 25-30% capacity utilization to stop the current cash burn of ~₹10 Cr per quarter.
⚠ அபாய எச்சரிக்கைகள்
Persistent losses in the API segment
High interest burden relative to operating cash flow
Low capacity utilization in new business lines
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the API segment's revenue growth; the company previously indicated a ₹100 Cr annual revenue target is needed for cash break-even, while current quarterly run-rates are significantly lower.
Natural Capsules FY26 Revenue Up 11% to ₹187.2 Cr; Posts Net Loss of ₹24.66 Cr on API Costs
Natural Capsules Limited reported a consolidated net loss of ₹24.66 crore for FY26, compared to a profit in the previous year, despite an 11% growth in revenue to ₹187.20 crore. The profitability was severely impacted by operational disruptions at the Puducherry plant and high pre-commercial overheads, depreciation, and interest costs from the new API subsidiary, Natural Biogenex. While Q4 FY26 showed a sequential recovery with revenue of ₹58.45 crore and a return to positive EBITDA (₹1.33 crore), the company faces significant liquidity pressure and is exploring fundraising through BIRAC schemes, preferential allotments, or rights issues.
முக்கிய அம்சங்கள்
FY26 consolidated revenue grew 11% YoY to ₹187.20 crore, but EBITDA margins dropped from 10.35% to -0.83%.Q4 FY26 revenue surged 55% QoQ to ₹58.45 crore, aided by clearing a backlog of deferred dispatches from the Puducherry facility.Finance costs rose to ₹10.95 crore and depreciation to ₹17.14 crore as the Tumkur API facility entered its operational cycle.Installed capsule capacity increased to 25 billion per annum, with the new HPMC line expected to contribute revenue in H2 FY27.Management is targeting a return to consolidated profitability in FY27 through improved product mix and API commercialization.
👀 கவனிக்க வேண்டியவை
Investors should remain cautious as the company navigates a liquidity crunch and high debt servicing costs following its API expansion. Key triggers to watch include the successful execution of the proposed fundraising and the timely regulatory approval for HPMC capsule exports to the US market in H2 FY27.
Natural Capsules Q4FY26 Revenue Jumps 30% Y-o-Y to ₹58.45 Cr; Reports Net Loss of ₹4.98 Cr
Natural Capsules reported a strong sequential recovery in Q4FY26 with revenue growing 55% Q-o-Q to ₹58.45 crore, primarily driven by clearing deferred orders from the Puducherry plant. Despite the topline growth, the company posted a consolidated net loss of ₹4.98 crore for the quarter and a significant ₹24.66 crore loss for the full year FY26. Profitability was hampered by a 73% Y-o-Y increase in finance costs and an 88% rise in depreciation following heavy investments in the API segment. Management expects stability in FY27 as commercial API sales have commenced and a new HPMC capsule line is set to contribute from H2 FY27.
முக்கிய அம்சங்கள்
Q4FY26 Revenue increased 30% Y-o-Y to ₹58.45 crore, supported by ₹36 crore in deferred dispatches from the previous quarter.Consolidated EBITDA for the quarter stood at ₹1.33 crore, down 70% Y-o-Y, with margins compressing to 2.28%.Full-year FY26 net loss widened to ₹24.66 crore from a profit of ₹0.62 crore in FY25 due to high operational and capital costs.Total capsule manufacturing capacity reached 20.25 Billion Capsules per Annum (BCPA) with the addition of a new HPMC line.Subsidiary Natural Biogenex entered a definitive agreement with Fermbox Bio for fermentation-based CDMO services to improve asset utilization.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the scaling of the API business and the margin profile of the new HPMC line starting H2 FY27. While revenue recovery is visible, the high debt servicing and depreciation costs necessitate a cautious approach until bottom-line breakeven is achieved.
Natural Capsules Q4 Revenue Up 55% QoQ to ₹58.45 Cr; API Commercial Sales Commence
Natural Capsules Limited reported a sequential recovery in Q4 FY26 with revenue of ₹58.45 Cr, up 55% QoQ, primarily due to clearing deferred dispatches from its Puducherry plant. Despite the quarterly improvement, the company ended FY26 with a net loss of ₹24.66 Cr and a negative EBITDA margin of 0.83%. A key positive is the commencement of commercial API sales and a new CDMO agreement with Fermbox Bio to boost fermentation asset utilization. Management expects a more stable FY27 with new HPMC capsule lines contributing in the second half.
முக்கிய அம்சங்கள்
Q4 FY26 revenue grew 55% QoQ to ₹58.45 Cr, while EBITDA turned positive at ₹1.33 Cr.Full-year FY26 revenue remained flat at ₹187.20 Cr with a substantial net loss of ₹24.66 Cr.Commercial sales in the API segment finally began in Q4 FY26 after previous delays.Signed a Framework and Contract Manufacturing Agreement with Fermbox Bio for fermentation-based CDMO.New HPMC line for double-zero capsules is ready for production, targeting US markets in H2 FY27.
👀 கவனிக்க வேண்டியவை
Monitor the scale-up of the API segment and the impact of the Fermbox Bio partnership on asset utilization. The stock remains a watch until the company demonstrates consistent quarterly profitability and successful US market entry for its new capsule line.
Natural Capsules Approves FY26 Results, Appoints New CS, and Allots 25,000 ESOP Shares
Natural Capsules Limited has approved its audited financial results for the fiscal year ended March 31, 2026, receiving an unmodified auditor's opinion with a reported diluted EPS of Rs. 10.72. The company appointed Mr. Akshay Dutta as the new Company Secretary and Compliance Officer and re-appointed Mr. Laxminarayana Moondra as Whole-time Director for a three-year term. Additionally, the board allotted 25,000 equity shares under the ESOP 2025 plan, increasing the total paid-up share capital to Rs. 10.41 crore. These moves signify a focus on governance and leadership continuity.
முக்கிய அம்சங்கள்
Approved audited standalone and consolidated financial results for the year ended March 31, 2026, with an unmodified audit opinion.Appointed Mr. Akshay Dutta as Company Secretary and Compliance Officer effective May 27, 2026.Allotted 25,000 equity shares of Rs. 10 each under ESOP 2025, increasing paid-up capital to Rs. 10,41,11,540.Re-appointed Mr. Shri Laxminarayana Moondra as Whole-time Director for a 3-year term starting July 28, 2026.Reported a diluted earnings per share (EPS) of Rs. 10.72 for the financial year 2025-26.
👀 கவனிக்க வேண்டியவை
Investors should monitor the full financial statements for FY26 to evaluate operational performance beyond the reported EPS. The management re-appointments and new compliance officer provide stability in corporate governance.
Natural Capsules Subsidiary Natural Biogenex to Raise ₹1.11 Crore via Rights Issue
Natural Capsules Limited's material subsidiary, Natural Biogenex Private Limited, has approved a rights issue of 11,11,200 equity shares. The shares are priced at a face value of ₹10 each, resulting in a total fundraise of ₹1,11,12,000. This capital infusion is aimed at strengthening the subsidiary's financial position. Investors should note that this is a relatively small capital raise for a material subsidiary.
முக்கிய அம்சங்கள்
Material subsidiary Natural Biogenex Private Limited to issue 11,11,200 equity sharesIssue price set at ₹10 per share (at par), totaling ₹1.11 croreBoard approval for the rights issue was granted on May 27, 2026Disclosure made under Regulation 30(9) of SEBI (LODR) Regulations
👀 கவனிக்க வேண்டியவை
Monitor whether Natural Capsules Limited subscribes to its portion of the rights issue to maintain its stake. The small quantum suggests routine capital needs rather than a major strategic shift.
Natural Capsules Limited (NATCAPSUQ) has successfully passed a special resolution to enhance its limits for investments, loans, guarantees, and securities under Section 186 of the Companies Act. The resolution was approved via postal ballot with an overwhelming majority of 99.9962% votes in favor. This regulatory milestone provides the company with increased financial flexibility to support its growth objectives or subsidiary requirements. The voting process concluded on March 27, 2026, with strong participation from the promoter group and non-institutional public shareholders.
முக்கிய அம்சங்கள்
Special Resolution passed to increase limits for investments, loans, and guarantees under Section 186 of the Companies Act.The resolution received 99.9962% approval, with 5,296,294 votes in favor and only 201 votes against.Promoter group participation was high at 99.61% of their holdings, with 100% of their polled votes in favor.The approval grants the company greater headroom for capital deployment and inter-corporate financial support for future projects.
👀 கவனிக்க வேண்டியவை
The approval indicates strong shareholder trust in management's capital allocation strategy; investors should monitor future announcements for specific investments or expansion plans that utilize these new limits.
Natural Capsules Limited has received credit ratings from Infomerics Valuation and Rating Limited for bank facilities totaling Rs 59.15 crores. The rating agency assigned 'IVR BB+' with a Stable outlook for long-term facilities worth Rs 56.35 crores and 'IVR A4+' for short-term facilities of Rs 2.80 crores. These ratings reflect the company's current creditworthiness across various loan instruments from lenders like SBI and HDFC Bank. The stable outlook suggests that the rating is unlikely to change in the near term.
முக்கிய அம்சங்கள்
Total bank facilities rated at Rs 59.15 crores across multiple lenders.Long-term facilities of Rs 56.35 crores assigned IVR BB+ rating with a Stable outlook.Short-term facilities of Rs 2.80 crores assigned IVR A4+ rating.Major debt exposure includes HDFC Bank (Rs 28.15 Cr) and State Bank of India (Rs 25.30 Cr) for term loans and cash credit.
👀 கவனிக்க வேண்டியவை
The BB+ rating is considered speculative grade (just below investment grade), indicating moderate credit risk. Investors should monitor the company's financial performance for potential upgrades to investment-grade status (BBB- or higher) which could lower future borrowing costs.
Natural Capsules Subsidiary Signs ₹60 Cr Strategic CDMO Agreement with Fermbox Bio
Natural Biogenex, a material subsidiary of Natural Capsules Limited, has entered into a strategic framework agreement with Fermbox Bio to bolster fermentation-based CDMO capabilities. As part of the deal, Fermbox will provide equipment worth up to ₹60 crore at NBPL's Tumkur facility. This collaboration enables the company to target global biopharma and industrial biotech clients using advanced fermentation technology. The partnership is strategically timed to benefit from India's BioE3 Policy and the growing global demand for outsourced biomanufacturing.
முக்கிய அம்சங்கள்
Natural Biogenex (NBPL) signs definitive agreements with Fermbox Bio for fermentation-based CDMO services.Fermbox Bio to provide advanced equipment placement and technology worth up to ₹60 crore at NBPL’s Tumkur plant.NBPL will handle GMP-compliant manufacturing, quality assurance, and regulatory compliance for the partnership.The collaboration targets high-value segments in both pharmaceutical and industrial biotechnology.The move aligns with the Indian government's BioE3 Policy to accelerate biomanufacturing innovation.
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant value-accretive step into high-margin CDMO services. Monitor the operationalization of the ₹60 crore equipment and the subsequent impact on the subsidiary's order book and margins.
Natural Capsules Seeks Approval to Increase Investment and Loan Limits to ₹250 Crore
Natural Capsules Limited has issued a postal ballot notice to seek shareholder approval for increasing the limits of investments, loans, and guarantees under Section 186 of the Companies Act. The company is proposing a new aggregate limit of ₹250 Crore, which would allow the Board greater flexibility in capital deployment and inter-corporate financial support. The approval is being sought through a special resolution via electronic voting. This move suggests the company may be preparing for future expansions, acquisitions, or strategic investments.
முக்கிய அம்சங்கள்
Proposed enhancement of limits for loans, investments, and guarantees to a maximum of ₹250 Crore.Approval sought via Special Resolution through a Postal Ballot process conducted electronically.E-voting period is scheduled from February 26, 2026, to March 27, 2026.The cut-off date for determining shareholder eligibility for voting was February 20, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the outcome of the vote and subsequent announcements to see how the company intends to utilize this significantly higher limit of ₹250 Crore. While it provides operational flexibility, the specific deployment of these funds will determine the long-term impact on shareholder value.
Natural Capsules Q3 FY26: Revenue drops 14% Y-o-Y to ₹37.75 Cr; Net Loss at ₹7.12 Cr
Natural Capsules reported a weak Q3 FY26 with consolidated revenue declining 14% Y-o-Y to ₹37.75 Cr, primarily due to a temporary regulatory shutdown of its Puducherry unit. The company posted a net loss of ₹7.12 Cr compared to a marginal profit in the previous year, as EBITDA margins crashed to -6.16% from 9.73% Y-o-Y. While the Puducherry plant has resumed operations and US tariffs on HPMC capsules have eased, the API fermentation block continues to face commercial scale-up challenges. Management is now exploring contractual partnerships to improve asset utilization and expects a recovery in Q4 FY26.
முக்கிய அம்சங்கள்
Consolidated Revenue fell 14% Y-o-Y to ₹37.75 Cr due to regulatory issues and deferred dispatches at the Puducherry facility.EBITDA turned negative at -₹2.33 Cr, with margins contracting by 1,589 bps Y-o-Y to -6.16%.Net Loss for the quarter stood at ₹7.12 Cr, bringing the 9M FY26 total loss to ₹19.69 Cr.US trade tariffs on HPMC capsules have been eased, restoring growth visibility in the North American market.Company is in advanced talks with partners for contract manufacturing at its fermentation block to mitigate technical scale-up delays.
👀 கவனிக்க வேண்டியவை
Investors should maintain a cautious stance given the significant bottom-line erosion and execution hurdles in the API segment. Monitor Q4 results closely to verify management's guidance on operational recovery and the finalization of fermentation block partnerships.
Natural Capsules Q3 Net Profit Crashes 79% YoY to ₹36 Lakhs; Allots 45,000 ESOP Shares
Natural Capsules reported a significant decline in financial performance for the quarter ended December 31, 2025. Standalone revenue fell 21% YoY to ₹34.15 crore, while net profit plummeted 79% YoY to just ₹0.36 crore. On a consolidated basis, the company barely broke even with a net profit of ₹0.10 crore. The board also approved the allotment of 45,000 equity shares under its ESOP scheme and is seeking to increase its investment limits via postal ballot.
முக்கிய அம்சங்கள்
Standalone Net Profit declined sharply to ₹36.23 Lakhs from ₹170.32 Lakhs in the previous year's quarter.Revenue from operations decreased to ₹3,414.64 Lakhs compared to ₹4,341.18 Lakhs YoY.Consolidated Net Profit for Q3 FY26 stood at a marginal ₹10.33 Lakhs, down from ₹250.78 Lakhs in Q2 FY26.Paid-up share capital increased to ₹10.38 Crore following the allotment of 45,000 ESOP shares at ₹10 each.Board approved a postal ballot to enhance limits for loans and investments under Section 186 of the Companies Act.
👀 கவனிக்க வேண்டியவை
The results show a severe deterioration in profitability and margins that warrants immediate caution. Investors should wait for management commentary to understand if these headwinds are transitory or structural before considering any new positions.
Natural Capsules Subsidiary Cancels Rights Issue Due to Non-Subscription
Natural Capsules Limited's material subsidiary, Natural Biogenex Private Limited, has decided to cancel its planned Rights Issue. The decision was finalized during a board meeting on January 03, 2026, following the non-subscription of shares by the major shareholder. This Rights Issue was previously announced on September 30, 2025, and its cancellation indicates a setback in the subsidiary's capital raising efforts. Investors should note that this could impact the subsidiary's planned projects or debt management.
முக்கிய அம்சங்கள்
Material subsidiary Natural Biogenex Private Limited cancels Rights Issue allotment.Cancellation is attributed to non-subscription by the major shareholder.The Rights Issue was originally initiated following an intimation on September 30, 2025.Board decision to halt the process was made on January 03, 2026.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution and seek clarity on how the subsidiary intends to meet its funding requirements following this failed Rights Issue. Monitor for any further updates regarding the financial health or strategic direction of Natural Biogenex.
Natural Capsules Receives Temporary Closure Order for Pondicherry Plant
Natural Capsules Limited has been directed by the Department of Drug Controller to temporarily cease operations at its Pondicherry manufacturing plant as of December 26, 2025. The regulatory action was triggered by the company supplying material to a customer whose drug license had expired. While the company has initiated corrective actions and is seeking revocation of the order, the immediate halt in production poses an operational risk. The management is currently assessing the specific financial impact resulting from this shutdown.
முக்கிய அம்சங்கள்
Department of Drug Controller ordered temporary closure of the Pondicherry plant on December 26, 2025The regulatory violation involved supplying materials to a client with an expired drug licenseCompany has initiated corrective measures and is preparing documents for revocation of the orderTotal financial impact of the operational halt is yet to be quantified by the management
👀 கவனிக்க வேண்டியவை
Investors should remain cautious and monitor the company's updates regarding the restart of the Pondicherry plant. Any prolonged closure could significantly impact the upcoming quarterly production volumes and revenue.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
